Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults

A prospective, randomised, observer-blind, comparative study was performed in healthy adults with a new hepatitis A/typhoid combined vaccine, Viatim™, and the marketed Hepatyrix™ vaccine. Both vaccines induced high levels of protective antibodies, but typhoid responses were higher and hepatitis A responses more rapid with Viatim™ compared with Hepatyrix™. Both vaccines were well tolerated, no serious adverse events (SAEs) occurred, but more Viatim™ vaccinees had more mild or moderate local reactions (82.7%) than Hepatyrix™ (53.1%, p < 0.001). In this direct comparison Viatim™ induced more local reactions, but elicited a more rapid and higher immune response to both antigens than Hepatyrix™.